Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Campus Vienna Biocenter - Progress on Alzheimer’s Vaccine

16.09.2005


An innovative vaccination can significantly reduce deposits of the substances in the brain responsible for causing Alzheimer’s disease. This result was disclosed today by Affiris GmbH, a company located at the Campus Vienna Biocenter, Austria. The rapid progress during the pre-clinical development phase has already enabled the Vienna-based company, although having operated only since April 2004, to plan clinical trials for 2006, and thus proves the international competitiveness of the Campus Vienna Biocenter.



Beta-amyloids are pathological fragments of a normal brain protein. They are responsible for the development of Alzheimer’s disease, as they cause the death of brain cells. Amyloid fragments are found in large amounts in the cerebral fluid of Alzheimer patients. Deposits are formed in the brain over the years, thus creating the plaque structures typical of Alzheimer’s disease. It has not yet been completely clarified whether plaque formation or the soluble beta-amyloids are the causative agents for Alzheimer’s disease.

Tailor-made Vaccine


The Vienna-based company Affiris is now reporting that it has succeeded in significantly reducing Alzheimer plaques by at least two-thirds in pre-clinical models by means of an innovative vaccine. CEO Dr. Walter Schmidt explains the important feature of the vaccination strategy: "Alzheimer’s is caused by a fragment of one of the ubiquitous proteins of cerebral cells. If one wants to combat Alzheimer immunologically it is essential to generate antibodies which are targeted against the beta-amyloids, but which leave the normal constituent of the cerebral cells unharmed, since the latter would induce an autoimmune disease. In keeping with this, Affiris´ vaccine approach has been shown to be highly specific for beta amyloids and not to react with the normal constituent of cerebral cells."

Thus, the Affiris approach not only avoids an autoimmune disease, but also offers the advantage of targeting simultaneously both the plaques and the soluble beta-amyloid fraction. Therefore, whether the soluble or plaque forms - or both - are responsible for causing the disease is not ultimately crucial for the vaccine’s success. The additional proof that the vaccine induces antibodies, which are active against plaques in human tissue samples, and the first data collected on the toxicology profile have further contributed to built a secure basis for Affiris to schedule the first trials on patients for 2006.

Biotech with Economics

Beside its scientific success Affiris also boasts important economic advantages: low costs and short manufacturing times for its vaccine. In the words of Dr. Schmidt: "Our substances are produced at low costs and a building-block system is used to form the vaccine. The effective component is synthetically manufactured and combined with a carrier substance isolated from natural resources. Both together form the actual vaccine and a standard adjuvant is added to strengthen the immune response."

The fact that the management has taken these important economic aspects into consideration from the very beginning is also due to the comprehensive biotech experiences at the Campus Vienna Biocenter. After all, numerous biotech companies and research institutes are situated at the Campus Vienna Biocenter, in addition to the FH Campus Wien (biotechnology), the Life Science Departments of the University of Vienna and the Medical University of Vienna, all sharing both resources and experiences and thus contributing to the international success of this location.

About AFFiRiS (September 2005):

AFFiRiS develops peptide-based vaccines for the treatment of Alzheimer’s disease and atherosclerosis. The company has established platform technologies and registered seven patents. 12 employees work in a 6,500 sqf rented laboratory facility on the Campus Vienna Biocenter.

About the Campus Vienna Biocenter (September 2005):

The Campus Vienna Biocenter is one of the largest R&D clusters in Austria with approx. 1,000 scientists from 40 nations at 16 organisations. Academic departments (University of Vienna, Medical University of Vienna, subsumed in the Max F. Perutz Laboratories), private research institutes (IMP - Institute of Molecular Pathology) and institutes of the Austrian Academy of Sciences (IMBA - Institute of Molecular Biotechnology, GMI - Gregor Mendel Institute) are also located here along with commercial R&D companies, service companies and training course centres.

Till C. Jelitto | alfa
Further information:
http://www.prd.at
http://www.affiris.com
http://www.viennabiocenter.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>